Skip to main content

Vizz FDA Approval History

Last updated by Judith Stewart, BPharm on Aug 4, 2025.

FDA Approved: Yes (First approved July 31, 2025)
Brand name: Vizz
Generic name: aceclidine
Dosage form: Ophthalmic Solution
Previous Name: LNZ100
Company: LENZ Therapeutics, Inc.
Treatment for: Presbyopia

Vizz (aceclidine) is a cholinergic agonist indicated for the treatment of presbyopia in adults.

Development timeline for Vizz

DateArticle
Aug  1, 2025Approval FDA Approves Vizz (aceclidine ophthalmic solution) for the Treatment of Presbyopia
Oct 21, 2024LENZ Therapeutics Announces FDA Acceptance of New Drug Application for LNZ100 for the Treatment of Presbyopia
Aug 12, 2024LENZ Therapeutics Announces Submission of New Drug Application to U.S. Food and Drug Administration for LNZ100 for the Treatment of Presbyopia
Apr  3, 2024LENZ Therapeutics Announces Positive Topline Data from Aceclidine Phase 3 CLARITY Presbyopia Trials

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.